Company* |
Company* |
Type/Product Area | Terms/Details (Date) |
Acadia Pharmaceuticals |
Sepracor Inc. (SEPR) |
They will jointly research and develop agonists and antagonists of selective muscarinic receptors for CNS disorders, including Acadia's m1 agonist program |
Sepracor is buying $10M of Acadia stock at a 40% premium, and will buy up to $10M more in stock at a 25% premium in one year; Acadia also will get research funding for three years; a single approval would result in $40M of payments to Acadia, plus royalties on sales (1/11) |
Achillion |
Gilead Sciences Inc. (GILD) |
Gilead got worldwide rights to small-molecule compounds for treating hepatitis C virus |
Achillion gets $5M up front and a $5M equity investment, as well as partial research funding; it could earn more than $100M in milestone payments, as well as royalties on sales; the deal's value would increase if related compounds are developed (11/29) |
AdnaGen AG* |
Gen-Probe Inc. (GPRO) |
Gen-Probe licensed technology for detecting rare, circulating tumor cells that are an early event in metastasis |
Gen-Probe gets exclusive access for molecular diagnostic tests for prostate and bladder cancers; AdnaGen gets $1.75M in license fees, up to $2.25M in milestones, and royalties on any resulting sales (1/3) |
AEterna |
Keryx Biopharmaceuticals Inc. (KERX) |
Keryx got certain rights to develop and sell ErPC in North America, South Africa, Israel, Australia and New Zealand |
The product, designed to block PI3K-AKT pathways, is an analogue of perifosine, for which Keryx already had North American rights; terms were not disclosed (1/6) |
Affitech A/S* |
Dyax Corp. (DYAX) |
Cross-licensing agreement covering phage display technologies |
The deal involves Affitech's "Breitling" and Dyax's "Ladner" family of patents; terms of the deal were not disclosed (11/29) |
Alnylam |
GeneCare Research Institute Co. Ltd. (Japan) |
GeneCare got an exclusive license to develop RNAi therapeutics against two DNA helicase genes associated with cancer |
Alnylam gets up-front and annual payments, as well as potential milestones and royalties; it also kept the right to negotiate co-development and -promotion deals on the products in the U.S. (1/6) |
Altair Nano- |
Spectrum Pharmaceuticals Inc. (SPPI) |
Spectrum acquired worldwide rights to RenaZorb (two second-generation lanthanum- based phosphate binding agents) |
Spectrum will make an up-front payment of 100,000 shares of restricted stock and make a $200,000 equity investment; Altair also is eligible to receive milestone and royalty payments (1/31) |
Antigenics |
Pharmexa A/S (Denmark; CSE: PHARMX) |
Pharmexa licensed an adjuvant for use with its HER-2 Protein AutoVac pharmaccine |
Pharmexa will formulate the pharmaccine with the QS-21 adjuvant; terms of the deal were not disclosed (1/18) |
Applied |
Inpharmatica Ltd.* (UK) |
Applied InSilico will apply its ADME technologies to research at Inpharmatica |
Inpharmatica will use the technologies to advance its Admensa platform; terms of the contract were not disclosed (12/6) |
Array |
InterMune Inc. (ITMN) |
InterMune got expanded rights to certain compounds under their September 2002 collaboration to discover drugs for hepatitis C |
Array gets a $2.5M payment, while all other terms remain the same; under a new deal, InterMune has an exclusive option through March 2005 to access Array's discovery platform for targets in hepatology; Array could get research, milestone and royalty payments if a target is selected (12/7) |
Asinex Ltd.* |
Biovitrum AB* (Sweden) |
Deal to discover and optimize leads for multiple Biovitrum targets in metabolic diseases |
Asinex will be eligible for milestone and royalty payments; separately, it will provide chemistry services for other targets on a fee-for-service basis (11/24) |
Atugen AG* |
Asinex Ltd.* (Russia) |
Collaboration to discover and develop cancer drugs targeting the kinase PKN3 |
They will work on the program on a shared- risk basis; any revenues would be equally divided (2/7) |
BioImage A/S* |
Definiens AG* (Germany) |
Agreement to deliver tailored applications to the high- content screening market |
They will pool certain technologies in the worldwide, nonexclusive deal, which also includes a co-development element (12/6) |
BioKine |
BioTie Therapies Corp. (Finland; HEX:BTH1V) |
BioTie gained exclusive rights to develop the anti-inflammatory small-molecule compound BKT104 |
BioKine is entitled to receive milestone payments in the deal, along with royalties on any resulting sales (1/12) |
Biolex Inc.* |
Medarex Inc. (MEDX) |
Biolex will create a commercial line for an undisclosed Medarex monoclonal antibody |
At Medarex's option, Biolex may scale-up and manufacture the antibody following commercial-line creation; terms were not disclosed (2/4) |
Biovation Ltd.* |
Scancell Ltd.* |
Biovation will apply its DeImmunisation technology to up to two further Scancell antibodies, including SC101 |
The goal is to help prepare the antibodies for clinical trials; terms of the deal were not disclosed (1/11) |
Caliper |
Predicant Biosciences Inc.* |
Predicant got nonexclusive access to microfluidics technology for analyzing proteins using mass spectrometry |
Predicant is developing proteomic tests; terms of the deal were not disclosed (1/6) |
Cambridge |
NeurAxon Inc.* (Canada) |
Cambridge Bioscience will provide assay development and screening services to NeurAxon |
Terms and targets of the deal were not disclosed (11/25) |
CancerVax |
Serono SA (Switzerland; NYSE:SRA) |
Deal to develop and sell CancerVax's Canvaxin, an immunotherapy product in Phase III trials for advanced melanoma |
They will share development costs and, in the U.S., profits on an equal basis; Serono has rights outside the U.S. and would pay royalties on those sales; CancerVax gets $25M in signing fees and a $12M equity investment up front, and could receive up to $253M in milestone payments (12/15) |
Celladon |
Targeted Genetics Corp. (TGEN) |
Collaboration to develop adeno-associated virus-based gene therapies for treating congestive heart failure |
Targeted Genetics committed $2M toward development of AAV vectors containing the SERCA2a gene and phospholamban gene mutations, and is eligible to receive milestone and royalty payments (1/4) |
Cellectis SA* |
Lexicon Genetics Inc. (LEXG) |
Lexicon got rights to technology for the replacement or insertion of a gene in a eukaryotic genome |
Lexicon will use the technology in genetically modified mice research; terms of the worldwide, nonexclusive deal were not disclosed (11/22) |
Cellegy |
ProStrakan |
ProStrakan will market Cellegy's Rectogesic (Cellegesic) in Europe |
Cellegy gets up to $5.6M in up-front and milestone payments, as well as payments that exceed 25% of net sales in Europe (12/9) |
Cell |
DiaKine Therapeutics Inc.* |
DiaKine licensed the small molecule Lisofylline for development in diabetes and related complications |
CTI gets a license fee, potential milestone and royalty payments, and an equity interest in DiaKine; CTI retains all rights in non-diabetes applications (1/4) |
ChemDiv |
Entercel Ltd.* |
Entercel got access to ChemDiv's compound collection |
ChemDiv also will provide medicinal chemistry services; terms of the deal were not disclosed (12/16) |
ComGenex |
Echelon Biosciences Inc.* (subsidiary of AEterna Zentaris Inc.) |
They finalized deal to transfer to Echelon all rights to technology created in their collaboration |
The rights are to develop, manufacture and market certain PI3K inhibitors for cancer indications; terms of the deal were not disclosed (2/1) |
Control |
Alimera Inc.* |
Collaboration to develop and market a treatment for diabetic macular edema |
Alimera also has an option to develop three additional products using CDS's delivery technology; terms were not disclosed (2/16) |
Corixa Corp. |
Genentech Inc. (NYSE:DNA) |
Genentech got exclusive rights to an undisclosed target for development of humanized antibody-based therapeutics |
Corixa gets a $1.6M up-front license fee and up to $8.25M in milestone payments, as well as royalties on any sales (1/13) |
Corixa Corp. |
Gen-Probe |
Gen-Probe licensed rights to develop molecular diagnostic tests for about 50 potential genetic markers for various solid tumors |
Gen-Probe will pay Corixa a $1.6M access fee, $3.2M more over two years unless it ends the deal, and up to $2M per product in milestones, as well as royalties on any resulting sales (12/5) |
Crucell NV |
Genentech Inc. (NYSE:DNA) |
Genentech is evaluating Crucell's STAR technology for the production of antibodies and other proteins |
Genentech is funding the joint evaluation program, and has an option to sign a non- exclusive license agreement (1/7) |
Crucell NV |
Chiron Corp. (CHIR) |
Chiron got rights to use PER.C6 technology in manufacturing alphavirus vectors for vaccine research programs |
Terms of the nonexclusive research deal were not disclosed; it is Chiron's second license to the technology (12/22) |
Crucell NV |
Micromet AG* (Germany) |
Microment got a license to use the PER.C6 cell line for evaluating monoclonal antibodies and subsequent preclinical manufacturing |
Crucell and DSM will receive a research license payment and annual maintenance fees; further terms were not disclosed (11/19) |
Curis Inc. |
Genentech Inc. (NYSE:DNA) |
Curis exercised its U.S. co-development option to develop a product for topically treating basal cell carcinoma |
Curis now will share in costs and profits for the preclinical compound from their 2003 collaboration based on inhibition of the Hedgehog signaling pathway (2/1) |
Cyntellect |
Undisclosed company |
The company will access Cyntellect's Cell Xpress service |
Terms of the deal were not disclosed (1/27) |
Dharmacon |
Genentech Inc. (NYSE:DNA) |
Genentech will use Dharmacon RNAi technology for drug discovery and development |
Dharmacon will supply Genentech a range of siRNA reagents under undisclosed terms (1/21) |
Discovery |
Biovitrum AB* (Sweden) |
Deal to identify small-molecule lead compounds suitable for advancing targets in the metabolic disease area |
Biovitrum gets access to DPI's compound collection and its process and data tools; terms of the deal were not disclosed (12/14) |
Dyax Corp. |
Tanox Inc. (TNOX) |
Tanox got nonexclusive access to antibody phage display libraries to identify fully human antibodies |
Dyax gets an up-front license fee, annual license fees and potential milestone and royalty payments; target areas were not disclosed (11/29) |
Dyax Corp. |
Epix Pharmaceuticals Inc. (EPIX) |
Deal to use Dyax's phage display technology to discover peptides for use as imaging agents and/or therapeutics |
The deal, the second between the firms, will focus on an undisclosed Epix target; Epix will fund research at Dyax and make potential milestone and royalty payments (11/19) |
Epitomics |
InNexus Biotechnology Inc. (Canada; VSE:IXS) |
Deal to develop antibodies for certain targets that will be modified for delivery using InNexus' TransMab technology |
Epitomics will supply the antibodies; they plan to develop products through Phase II before licensing them out; financial details were not disclosed (1/12) |
Eurand |
Trigen Ltd.* (UK) |
Deal to develop controlled-release formulations of Trigen's oral anticoagulant, TGN 167 |
Eurand will develop a tablet form of the drug; Trigen retains all product rights; terms were not disclosed (11/24) |
Evotec OAI |
AnorMed Inc. (Canada; TSE:AOM) |
Evotec will support chemical development of AnorMED candidate AMD 3100 |
Evotec will complete the full validation of the process for the Phase III product under undisclosed terms (2/16) |
FIT Biotech |
Inovio A/S* (Norway) |
Program to develop FIT's HIV vaccine candidate with Inovio's Elgen gene delivery technology |
The agreement includes an option for FIT to negotiate a co-development/license deal for moving the program into clinical trials; terms were not disclosed (11/17) |
Galapagos |
Celgene Corp. (CELG) |
Galapagos will provide its adenoviral siRNA and cDNA libraries in a target discovery collaboration |
Celgene will use the SilenceSelect and FLeXSelect technologies across its research programs; terms of the deal were not disclosed (11/18) |
GenData |
Amgen Inc. (AMGN) |
Amgen will sponsor research for discovery and development of therapeutics and diagnostics for an undisclosed disorder |
Amgen will select genetic targets identified by GenData's population genetics discovery platform; specific terms were not disclosed (1/5) |
GeneGo Inc.* |
RNA Co. Ltd.* (Japan) |
RNA Co. licensed GeneGo's MetaCore technology for use in RNAi drug discovery |
Terms of the deal were not disclosed (1/24) |
Generation |
Qiagen NV (the Netherlands; QGEN) |
Qiagen licensed a technology for haplotype-specific extraction of DNA |
Qiagen subsidiary GenoVision Inc. got exclusive rights to the technology in all applications; terms were not disclosed (2/14) |
GlobeImmune |
MycoLogics Inc.* |
MycoLogics gained rights to develop certain antifungal products under the Globe-Immune Tarmogen Technology |
MycoLogics plans to begin preclinical testing of human and animal vaccines targeting fungal diseases; terms of the deal were not disclosed (1/17) |
GPC Biotech |
Debiopharm SA* (Switzerland) |
Debiopharm licensed GPC's preclinical small-molecule MHC Class II antagonists program |
Debiopharm will make up-front and potential milestone and royalty payments in exchange for worldwide rights (12/17) |
Helix |
Lumera Corp. (LMRA) |
Lumera exclusively licensed Helix's Biochip technology for developing protein chip sets |
Helix is entitled to up-front, milestone and royalty payments, and retains the right to use the technology in its research (1/25) |
HMGene Inc.* |
WellGen Inc.* |
HMGene will screen WellGen compounds against its panel of genes involved in adipocyte development |
Terms of the research contract and licensing deal were not disclosed; WellGen would commercialize any resulting products (2/10) |
Iceland |
Sequenom Inc. (SQNM) |
Deal to analyze Sequenom genetic markers associated with breast and prostate cancer in Icelandic patient samples |
Sequenom has commercialization rights for any resulting products, while Iceland Genomics is entitled to receive royalties on any sales (2/9) |
Iceland |
Aclara BioSciences Inc. (ACLA) |
Agreement to analyze tumor samples to validate candidate biomarkers |
IGC will provide samples that Aclara will analyze using its eTag assays; Aclara will provide funding, and share resulting data (12/3) |
IGI Inc. |
Senetek plc (OTC BB:SNTKY) |
Deal to evaluate IGI's Nova- some and micellar nanoparticle technologies for topical delivery of Senetek's Invicorp erectile dysfunction therapy |
The deal was disclosed at the same time as Sentek's offer to merge with IGI in a 50-50 deal; terms of the collaboration were not disclosed (1/14) |
ImClone |
Genentech Inc. (NYSE:DNA) |
ImClone licensed rights to patents covering aspects of antibody technology |
The licenses relate to the EGFR-targeted antibodies Erbitux and IMC-11F8; terms were not disclosed (1/25) |
Incyte Corp. |
Biosite Inc. (BSTE) |
Biosite exercised a semi- exclusive research and diagnostics license, and got an exclusive option to license 50 other diagnostic targets |
Incyte has received up-front fees, and could receive additional milestones and royalties should Biosite develop and commercialize diagnostic products using any of the targets (2/7) |
Intercell AG* |
SciGen Ltd.* (Singapore) |
They entered an exclusive agreement to develop a therapeutic vaccine for hepatitis B virus |
The effort will combine an Intercell adjuvant with an already-licensed antigen from SciGen; they will share costs and ownership of resulting products (12/13) |
Isis |
Sarissa Inc.* |
Sarissa licensed an antisense inhibitor of thymidylate synthase, which has applications in cancer |
Isis gets a $1M up-front fee in stock and potential milestone and royalty payments; Sarissa gets exclusive, worldwide rights (2/14) |
Ludesi AB* |
WITA GmbH* (Germany) |
Collaboration to provide information on protein functions in human, animal and plant cell cultures |
They plan to offer a proteomics solution that offers speed advantages; terms were not disclosed (11/18) |
MacroMed |
Diatos SA* (France) |
Diatos got exclusive rights to develop and sell OncoGel (injectable paclitaxel) worldwide except North America and Korea |
They will collaborate on clinical development; MacroMed gets a license fee and potential milestone and royalty payments, and retained the right to supply the product (1/5) |
Medarex Inc. |
PharmAthene Inc.* |
Collaboration to develop Medarex's fully human anti- body MDX-1303, which targets the Bacillus anthracis protective antigen |
Medarex gets an initial fee and would get an undisclosed share of any profits; PharmAthene will fund all future activities that are not supported by government funds (12/6) |
Medarex Inc. |
MedImmune Inc. (MEDI) |
Deal initially focused on development of Medarex's MDX-1103 and MDX-1333, preclinical antibodies that target autoimmune diseases |
Medarex gets $15M up front and an option prior to pivotal studies to elect to co-develop the products in return for co-promotion rights in the U.S.; otherwise, it would be eligible for milestone and royalty payments (11/23) |
MethylGene |
EnVivo Pharmaceuticals Inc.* |
Collaboration to develop small-molecule HDAC inhibitors for treating neurodegenerative disorders |
MethylGene, which will contribute chemistry expertise, gets $1.1M the first year; then they will share costs and revenues equally (2/8) |
Micromet |
EvoGenix Pty. Ltd.* (Australia) |
EvoGenix got a research license to patents in the field of single-chain antibodies |
Micromet gets an up-front payment, annual maintenance fees and sublicensing fees, which will be shared with Enzon Pharmaceuticals Inc. (12/23) |
Micromet |
Serono SA (Switzerland; NYSE:SRA) |
Deal for development of Micromet's fully human anti- body MT201, which targets the epithelial cell adhesion molecule |
Micromet gets $10M up front and milestone payments up to $138M if the product is approved in three or more indications; it also would get royalties on sales; Serono will take over development after completion of ongoing Phase II trials in cancer (12/7) |
Morphochem |
Probiodrug AG* (Germany) |
Deal to develop small-molecule drugs, initially focused on inhibition of the serine protease dipeptidyl peptidase IV for treating anxiety and depression |
Morphochem will identify compounds and Probiodrug will profile them; they each will retain an ownership interest in resulting intellectual property; terms were not disclosed (11/18) |
Nektar |
Zelos Therapeutics Inc.* |
Collaboration to develop an inhalable powder form of Zelos' parathyroid hormone analogue Ostabolin-C |
Nektar will develop the dry-powder drug and inhalation system, and get R&D funding along with potential milestone and royalty payments (1/24) |
NeoPharm |
Undisclosed company |
NeoPharm will provide customized NeoPhectin formulations for partner's compounds |
NeoPharm is entitled to payments of $500,000 over the next six months, and can negotiate a license agreement for any of the formulations that are developed (12/21) |
OctoPlus |
Biolex Inc.* |
Collaboration to co-develop a controlled-release formulation of recombinant human alfa interferon |
They will combine OctoPlus' biodegradable PolyActiv drug-delivery technology with Biolex's BLX-883; terms of the deal were not disclosed (2/16) |
OriGene |
Novasite Pharmaceuticals Inc.* |
Novasite licensed access to OriGene's TruClone collection of full-length human cDNAs |
Terms of the deal were not disclosed (2/15) |
OsteoScreen |
Neosil Inc.* |
Neosil licensed several hair-growth products from OsteoScreen |
Terms of the deal were not disclosed (2/16) |
Oxford |
Biogen Idec Inc. (BIIB) |
Biogen got rights to use Oxford's LentiVector technology in research activities |
Oxford gets an up-front license fee and annual maintenance payments; further terms were not disclosed (1/5) |
Oxford |
MolMed SpA* (Italy) |
MolMed got rights to use Oxford's in vivo gene delivery technology in development of its products |
Oxford gets an up-front license fee and annual maintenance payments, as well as potential milestone and royalty payments (12/13) |
Pepscan |
Cytos Biotechnology AG (Switzerland; SWX:CYTN) |
Research and option deal to identify peptide antigens for peptide-based therapeutic vaccines |
Pepscan will use its CLIPS technology to map and reconstruct the receptor interaction site of a cytokine that Cytos intends to target; terms were not disclosed (12/14) |
PharmaForm |
Auxilium Pharmaceuticals Inc. (AUXL) |
Auxilium got exclusive rights to develop and sell eight analgesic compounds using a transmucosal film technology |
The products will target acute and chronic pain; terms of the deal were not disclosed (2/8) |
ProMetic |
Octapharma AG* (Switzerland) |
Octapharma gained access to ProMetic's Mimetic Ligand affinity technology for the manufacture of protein drugs |
The deal was valued at C$1.4M to ProMetic (1/5) |
Proteom Ltd.* |
Prolysis Ltd.* (UK) |
Proteom will optimize antibiotic leads discovered by Prolysis |
Terms of the drug discovery agreement were not disclosed (12/2) |
Qualigen |
Gen-Probe Inc. (GPRO) |
Gen-Probe acquired an exclusive option to develop a point-of-use nucleic acid testing instrument |
Gen-Probe is paying $1M for an 18-month option to use an immunoassay platform for the clinical diagnostics, blood screening and industrial fields; it would pay $5.9M to $7M for 25% of Qualigen and up to $3M in license fees, as well as sales royalties, if it exercises the option (11/18) |
Rimonyx |
BioLineRx Ltd.* (Israel) |
BioLineRx got exclusive worldwide rights to develop BL-1030 |
BL-1030 is an L-selectin inhibitor targeted at inflammatory bowel disease; terms of the deal were not disclosed (1/13) |
Sareum Holdings plc (UK; AIM:SAR) |
EiRx Therapeutics plc (UK; AIM:ERX) |
Collaboration to discover and develop cancer therapies |
Sareum will apply its technologies to gene targets for cancer from EiRx; they plan to license resulting compounds after initial trials, and share resulting revenues (12/1) |
Sareum |
Millennium Pharmaceuticals Inc. (MLNM) |
Sareum will generate chemical compound libraries for use in Millennium drug discovery programs |
Terms of the fee-for-service deal were not disclosed (11/22) |
Seattle |
CuraGen Corp. (CRGN) |
CuraGen exercised its option to designate a second antigen target under their existing antibody-drug conjugate collaboration |
The option, stemming from their June 2004 collaboration, triggered a $1M payment to Seattle Genetics (2/15) |
Sertanty Inc.* |
Specs* (the Netherlands) |
Deal to design and produce small- molecule libraries targeting several kinase families |
Sertanty will design targeted libraries that Specs will offer to its worldwide customer base (12/21) |
Symbiontics Inc.* |
ZyStor Therapeutics Inc.* |
ZyStor acquired Glycosylation Independent Lysosomal Targeting technology |
The technology is designed to improve the effectiveness of therapeutics that replace missing lysosomal enzymes; terms were not disclosed (12/15) |
Targeted |
Sirna Therapeutics Inc. (RNAI) |
Collaboration using TGEN's adeno- associated virus delivery platform to develop drugs for Huntington's disease |
The AAV platform will be combined with Sirna's HD program and expertise in RNA silencing technologies; costs and any revenues will be shared (1/11) |
TheraSTrat AG* |
Discovery Partners International Inc. (DPII) |
TheraSTrat will apply its SafeBase Knowledge Base to aid discovery efforts at DPI |
They will apply genomics technologies to identify safety problems for individuals with relevant variations; terms of the deal were not disclosed (12/13) |
ThromboGenics |
BioInvent International AB (Sweden; SSE:BINV) |
They expanded collaboration to include a new class of anti-angiogenesis agents being developed by ThromboGenics |
Terms were not disclosed; the existing collaboration focuses on developing antibody-based drugs for cardiovascular indications (12/17) |
Trillium |
Genentech Inc. (NYSE:DNA) |
Genentech gained worldwide rights to TTI technology directed against an undisclosed target |
TTI gets an up-front payment, R&D funding and milestone payments; it also would get a royalty on sales; other terms were not disclosed (12/14) |
Tripos Inc. |
BioTie Therapies Corp. (Finland; HEX:BTH1V) |
Tripos will identify and optimize backup series for one of BioTie's drug discovery programs |
Tripos, using its LeadHopping technology, also will create compound libraries; terms of the multiyear deal were not disclosed (2/7) |
Vectron |
Pharmexa A/S (Denmark; CSE: PHARMX) |
Pharmexa acquired a portfolio of intellectual property rights in the field of immunotherapy |
Vectron is in liquidation; the technology includes targeted liposomal delivery systems and recombinant antibody-like proteins known as single-chain diabodies (12/22) |
Vertex |
Avalon Pharmaceuticals Inc.* |
Avalon gained exclusive rights to develop and sell VX-944, a Phase I IMPDH inhibitor, for treating various cancers |
Vertex will get up to $73M in up-front and milestone payments, and royalties on any sales; Vertex also has certain co-promotion rights in the U.S. and Europe (2/15) |
Xencor Inc.* |
Genentech Inc. (NYSE:DNA) |
Collaboration to use Xencor's XmAb technology to develop drugs against the antibody targets CD20 and Her2, and an undisclosed antigen |
Xencor gets $5M up front and annual license fees, as well as potential milestone payments for each target and royalties on any sales; Genentech's license is exclusive and worldwide (12/1) |
Xenova Group |
Oxxon Therapeutics Inc.* |
Oxxon got rights to use Xenova's DISC- SV Vector in various indications in oncology and infectious diseases |
The deal is worth up to $83M to Xenova in up-front and milestone payments, in addition to royalties on any sales; Oxxon also could get additional rights for additional payments; Xenova keeps rights for the prophylaxis of herpes virus diseases (1/13) |
Zyomyx Inc.* |
Invitrogen Corp. (IVGN) |
Invitrogen licensed rights to protein microarray patents for specific fields of use |
Invitrogen gets exclusive rights to patents covering a range of development processes for microarrays that use certain detection modalities; terms were not disclosed (11/30) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | |||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; HEX = Helsinki Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange. | |||
